Latest Research And Development News

Nufarm Limited reported a 3% revenue increase to $1.81 billion for the half-year ended March 2025, driven by Crop Protection volume growth. However, net profit after tax fell 39% amid fish oil pricing pressures and higher operating costs, prompting the board to withhold an interim dividend.

Light & Wonder unveiled ambitious growth targets and strategic plans at its 2025 Investor Day, spotlighting strong financial momentum and the integration of Grover Charitable Gaming. The company aims for $1.4 billion consolidated AEBITDA in 2025, underpinned by robust R&D and market leadership.

Ardea Resources has received a $1.2 million R&D tax incentive rebate from the Australian Government, reinforcing its innovative work at the Kalgoorlie Nickel Project and strengthening its financial position.

Noxopharm Limited has raised nearly $2.5 million by selling its entire stake in Nyrada Inc, providing non-dilutive capital to advance its HERACLES clinical trial and expand its research pipeline.

TechnologyOne Limited has reported a robust first half for FY25, with annual recurring revenue exceeding $500 million well ahead of schedule and profit before tax climbing 33%. The company’s SaaS+ platform and strategic acquisition of CourseLoop are driving growth and positioning it for ambitious long-term targets.

TechnologyOne has reported record half-year results, boosting full-year profit growth guidance to 13%–17%, driven by its pioneering SaaS+ ERP platform and strategic expansion.

Etherstack plc has reported its highest ever half-year cash receipts, surpassing US$7 million in the first half of FY2025, signaling strong momentum and a promising revenue outlook for the year.

HITIQ Limited has announced a non-renounceable entitlement offer to raise up to $2.92 million, supported by partial underwriting from GBA Capital and accompanied by new options issuance. The capital raise aims to fund expansion, product development, and operational growth.

Anteris Technologies has submitted its FDA Investigational Device Exemption for the pivotal PARADIGM Trial of its DurAVR heart valve and marked a milestone of 100 patients treated, while expanding manufacturing capacity amid rising R&D costs.

Anteris Technologies Global Corp. reported a $21.9 million net loss for Q1 2025, driven by increased R&D spending as it scales manufacturing and prepares pivotal trials for its DurAVR Transcatheter Heart Valve. The company’s recent $80 million IPO proceeds are being deployed to support these efforts and repay debt.

Life360, Inc. reported a strong Q1 2025 with 32% revenue growth to $103.6 million, driven by a 33% increase in subscription revenue and a return to profitability with $4.4 million net income. The company also advanced its strategic positioning through a $4.5 million acquisition and a key partnership.

Universal Biosensors reported a 6% increase in revenue for Q1 2025 but posted a net loss of A$3.84 million, with cash reserves sufficient only through Q3 2025, raising questions about its financial sustainability.